Tempus AI Inc. (TEM) is set for a defining month as it prepares to release its first-quarter earnings on May 5 and host its inaugural investor day on May 29. The company, which focuses on AI-driven precision oncology, has drawn attention from major pharma players, with Merck's CEO recently highlighting their collaboration during a quarterly call.
Market Position and Recent Performance
Tempus shares hovered near $55.44 on Friday, with a market capitalization of approximately $9.7 billion. The company reported full-year 2025 revenue of $1.27 billion, representing an 83.4% increase year-over-year, and has guided for 2026 revenue of around $1.59 billion. However, the company ended 2025 with a net loss of $245.0 million, though adjusted EBITDA narrowed to a loss of $7.4 million.
Key Catalysts: Earnings and Investor Day
Investors will closely watch the May 5 earnings call for updates on diagnostics growth, margins, and the 2026 outlook. The subsequent investor day on May 29 is expected to provide deeper insights into Tempus's strategy to transition from a diagnostics-focused company to a broader healthcare data and AI platform. Management, including CEO Eric Lefkofsky and CFO Jim Rogers, will present on the Diagnostics and Data & Applications segments.
Pharma Partnerships and Competitive Landscape
Tempus has expanded its alliance with Merck, granting access to its de-identified data and AI platform for biomarker discovery and drug development. Similarly, Gilead Sciences recently signed an enterprise-wide deal for Tempus's Lens platform. These partnerships are critical as Tempus faces stiff competition from Guardant Health and Roche's Foundation Medicine in the genomic diagnostics space. Guardant has also filed patent litigation against Tempus.
Insider Activity and Risks
An SEC filing revealed that entities linked to CEO Eric Lefkofsky sold 166,250 Class A shares on April 28 under a Rule 10b5-1 plan, at prices around $51.03 to $51.52. The company has flagged risks including competition, AI regulation, debt load, and integration of recent acquisitions like Paige AI, Ambry Genetics, and Deep 6 AI.
As May unfolds, Tempus must convince investors that its data contracts and test volumes can translate into sustainable profitability. The coming weeks will test whether the stock's valuation is justified by its growth trajectory.
